West Pharmaceutical Services, I (WST) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $330.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining.
West Pharmaceutical Services manufactures containment and delivery systems for injectable drugs—rubber stoppers, seals, drug delivery devices, and contract-manufactured components—for biologic, generic, and pharmaceutical companies globally. Top 10 customers represent 47.6% of... Read more
Hold if already holding. Not a fresh buy at $330.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — West Pharmaceutical Services, I
Latest news
- NEWS Insider Selling: West Pharmaceutical Services (NYSE:WST) CAO Sells 896 Shares of Stock - MarketBeat — MarketBeat negative
- NEWS West Pharmaceutical sr. VP Annette Favorite sells $859,753 in shares - Investing.com — Investing.com neutral
- NEWS West Pharmaceutical (WST) Upgraded to Strong Buy: Here's What You Should Know - Yahoo! Finance Canada — Yahoo! Finance Canada positive
- NEWS Are you looking for a top momentum pick? Why West Pharmaceutical Services (WST) is a great choice - MSN — MSN positive
- NEWS Are You Looking for a Top Momentum Pick? Why West Pharmaceutical Services (WST) is a Great Choice - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational (outside U.S.)57%10-K Item 1: 'Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025'
- MEDIUMCustomertop 10 customers48%10-K Item 1: 'Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025'
- LOWCustomerone customer (>10% of net sales)16%10-K Item 1: 'one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8%'
Material Events(8-K, last 90d)
- 2026-03-09Item 5.02HIGHCEO Eric M. Green informed the Board on March 6, 2026 of his intent to retire once his successor is hired to ensure a smooth transition. Board engaging executive search firm; transition expected in second half of 2026. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $330.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $324.26 (-1.7%), stop $302.97 (−8.9%), A.R:R -0.6:1. Score 6.1/10, moderate confidence.
Take-profit target: $324.26 (+1.4% upside). Target $324.26 (-1.7%), stop $302.97 (−8.9%), A.R:R -0.6:1. Stop-loss: $302.97.
Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining; Near 52-week high (3.4% away).
West Pharmaceutical Services, I trades at a P/E of 42.0 (forward 33.5). TrendMatrix value score: 3.3/10. Verdict: Hold.
22 analysts cover WST with a consensus score of 4.1/5. Average price target: $352.
What does West Pharmaceutical Services, I do?West Pharmaceutical Services manufactures containment and delivery systems for injectable drugs—rubber stoppers, seals,...
West Pharmaceutical Services manufactures containment and delivery systems for injectable drugs—rubber stoppers, seals, drug delivery devices, and contract-manufactured components—for biologic, generic, and pharmaceutical companies globally. Top 10 customers represent 47.6% of net sales; international sales account for 56.7% of consolidated net sales in 2025. The company operates in two segments: Proprietary Products and Contract-Manufactured Products.